Market's view on Skinbiotherap.
Published on April 2024
- SYME and OPTI offer comprehensive 10-year courses through financial insights and podcasts to assist understanding of their business models.
- Expectations are set for operational losses to either continue at the same rate or increase in the future, with recommendations to focus on subsequent strategies.
- Discussions around cost management and cash extraction methodologies to de-risk operations are prevalent.
- Forecasts suggest increases in revenue for various companies but worsening cash flows from operations, with no expected improvements in EPS or normalized net income.
- Comments indicate the perception of a significant pattern (“head and shoulders”) in monthly business trends, hinting at major ups and downs.
- Criticism is directed towards skinbiotiX, suggesting poor management decisions likened to flushing the business “down the toilet with bleach.”
- Positive acknowledgment of No.7 working without issues with Cath from Manchester Uni, seen as a strong endorsement.
- A complex discussion about the credibility and contributions of individuals in shared professional spaces, questioning the legitimacy of claims to fame or influence.
- A significant study on VHProbi® Mix R lotion demonstrated its effectiveness in enhancing skin barrier functions, suggesting potential collaborations or involvement of related companies in producing effective skincare products.